Sanofi and Regeneron's Dupixent: Advances against allergic fungal rhinosinusitis

Sanofi and Regeneron have achieved significant success with Dupixent in the treatment of allergic fungal rhinosinusitis (AFRS). The drug met endpoints in a Phase 3 study, demonstrating a substantial reduction in symptoms in patients aged 6 years and older. The Food and Drug Administration (FDA) has accepted Sanofi's application for priority review, potentially leading to approval on February 28, 2026.

The study shows that Dupixent reduces sinus opacity, nasal congestion, and polyps compared to placebo. If approved, Dupixent would be the first treatment specifically indicated for AFRS. AFRS is an inflammatory sinus condition, often found in hot and humid climates.

These advances represent an important step in the treatment of type 2 inflammatory diseases, paving the way for new therapeutic options for patients who currently have few effective resources.